Trial Profile
Phase II Study of the IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus in Patients With Relapsed/Refractory Multiple Myeloma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 12 Jan 2013
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Pasireotide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 09 Jan 2013 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 16 Nov 2010 New trial record